戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 Ki compared with WT RGS2 in a flow cytometry competition binding assay).
2 ed and validated a fluorescence polarization competition binding assay.
3 ide exchange binding assay and an HPLC-based competition binding assay.
4  independently our results with a minicircle competition binding assay.
5 -347, Lys-351, and Lys-414 was verified by a competition binding assay.
6 oluble Lf receptor activity as determined by competition binding assay.
7 d for their capacity to bind protein using a competition binding assay.
8 nding ability of all ELR+ chemokines using a competition binding assay.
9 ing to tissue homogenate using a radioligand competition binding assay.
10 sing ELISA, immunohistochemical studies, and competition binding assays.
11 d and synthesized compounds, were studied in competition binding assays.
12 ity of LY2795050 was measured in radioligand competition binding assays.
13  (hD3) receptor (Ki = 1-5 nM) as measured in competition binding assays.
14 as observed by coprecipitation, overlay, and competition binding assays.
15  higher than their respective Ki values from competition binding assays.
16 er of potency comparable to that observed in competition binding assays.
17 e observed HLA-DQ molecules was studied with competition binding assays.
18                                           In competition-binding assays, A-204197 competed with [3H]-
19 ma (PPARgamma), we identified GW9662 using a competition binding assay against the human ligand bindi
20  employed in an automated fluorescence-based competition binding assay, allowing the pKi values of se
21                   After in vitro testing via competition binding assay and autoradiography, [(18)F]PF
22 Evolution of pRNA aptamers was followed by a competition binding assay and nucleotide sequencing, and
23  to GPIIb/IIIa receptors was investigated in competition binding assays and autoradiography using a f
24                           Here, we have used competition binding assays and peptide binding assays to
25 ntagonists between the beta-lactamase assay, competition-binding assay, and other direct measurements
26                                              Competition binding assays at several serotonin receptor
27 as characterized by saturation, kinetic, and competition binding assays at the human, guinea pig, and
28                                Self-exchange competition binding assays between fluorescently labeled
29                                    The Blitz competition binding assay confirmed target binding of NU
30                                              Competition binding assays confirmed for all sera tested
31                                         In a competition binding assay, DAB4 bound EL4 murine thymic
32                                              Competition binding assays demonstrate that this binding
33                                     In vitro competition binding assays demonstrated that 1-4 have a
34                                     In vitro competition binding assays demonstrated that compounds 9
35          In vitro screening with radioligand competition binding assays demonstrated variable affinit
36 eta oligomer preparations makes conventional competition binding assays difficult to interpret.
37 ated PRP, and 4 nM in solid-phase GPIIb-IIIa competition binding assay (ELISA).
38 biological profiles evaluated using in vitro competition binding assays, ex vivo rat aortic ring bioa
39 ed in vitro in a transactivation assay and a competition binding assay for all RARs.
40 trategy for developing an optimal FRET-based competition binding assay for tyrosine kinases.
41                                           In competition binding assays FXI/PKA4, FXI/PKA4-Gly326, an
42 [N-methyl]-[(3)H]scopolamine methyl chloride competition binding assay in the presence of GTP.
43 d their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected
44 e rs6971 genetic polymorphism using in vitro competition binding assays in human brain and heart; ass
45 ide was also shown to be highly selective in competition binding assays in rat brain membranes.
46 to all five human receptors using direct and competition binding assays in solution.
47  heteromer has been evaluated by radioligand competition-binding assays in the absence and presence o
48                                   A solution competition binding assay, in which a surface immobilize
49 n significantly activate the AHR, and ligand competition binding assays indicate that I3S is a direct
50                                              Competition binding assays indicate that the binding of
51                                    Classical competition binding assays measure the binding of a labe
52 onists in [3H]5'-N-ethylcarboxamidoadenosine competition binding assays performed with yeast cell mem
53 urthermore, electromobility shift assays and competition binding assays reveal that Prx effectively u
54                                              Competition binding assays reveal that U2 snRNA (the hig
55                                            A competition binding assay revealed a dissociation consta
56                                              Competition binding assays revealed that the anti-SEE an
57                                           In competition binding assays, SET knockdown increased high
58                         By employing various competition binding assays, seven different types of bin
59                                              Competition binding assays show minimal dissociation of
60                                              Competition binding assays showed 11-25 and 27-31 bound
61  combined with cross-linking experiments and competition-binding assays showed that the fully disorde
62                                 Furthermore, competition binding assays suggest that Q509L decreases
63                                            A competition binding assay suggested a direct interaction
64             The pharmacological profile from competition binding assays suggests that the ligands may
65  analysis and/or by [125I]alpha-bungarotoxin competition binding assays the interactions of acetylcho
66                                           In competition binding assays, the affinity of agonists is
67 ing affinity but similar to those shown in a competition binding assay to displace radioiodinated ana
68 ioid receptors and are effective tracers for competition binding assays to evaluate NOPr-ligand affin
69                               In equilibrium competition binding assays to membranes from Sf9 cells i
70   We demonstrate the use of a DNA minicircle competition binding assay, together with DNA cyclization
71 nitor C protein-oligonucleotide binding in a competition binding assay under equilibrium conditions.
72                                         In a competition binding assay using the p85 PI 3-kinase C-te
73 ng was assessed in mobility shift assays and competition binding assays using cisplatin-damaged DNA.
74            Binding affinity was measured via competition binding assays using hB1R-expressing Chinese
75                         BIAcore analysis and competition binding assays using LOX human malignant mel
76 s and pharmacokinetic studies in mice and in competition binding assays using recombinant, soluble Fc
77                                              Competition binding assays using stably transfected L293
78                           Moreover, NanoBRET competition binding assays using TMR-Galphas19cha18 enab
79 68, and (nat)Ga-JMV5132 were determined in a competition-binding assay using GRPR-overexpressing PC-3
80                                      Using a competition binding assay, we have established that Klen
81                                      Using a competition binding assay, we show that the affinity of
82                                        Using competition binding assays, we find that short C-termina
83                                        Using competition binding assays, we further characterized thi
84             Using GW2331 as a radioligand in competition binding assays, we show that certain mono- a
85                                        Using competition binding assays, we show that the HAstV spike
86                                              Competition binding assays were conducted with (3)H-PK11
87 etic resonance spectroscopy and protein-drug competition binding assays were employed to define the g
88                                              Competition binding assays were employed to examine the
89                                 A BRET-based competition binding assay with 4 was also established an
90 e (Mr approximately 250-500 Da) ligands in a competition binding assay with cyclosporin A (CsA).
91                                              Competition binding assays with [(3)H]MRS2279 and P2Y1-R
92                                              Competition binding assays with b12 also showed that b12
93 tudy ligand-protein interactions by coupling competition binding assays with mass spectrometry-based
94                                              Competition binding assays with monoclonal antibodies is
95 ant (C1)4 and (C2)4 homotetramers along with competition binding assays with poly(A) and poly(C) indi
96               Selected probes were tested in competition binding assays with unlabeled competitors in